Anhui Pioneer Pharmaceutical Co., Ltd paid high attention to R&D work and established advanced domestic R&D centers, with a market-oriented, production-education-research combined R&D innovation system. The company was accredited by "national high and new technology enterprise" in 2012. Our R&D center was accredited by Hefei Enterprise R&D Center and Hefei Engineering Research Center (Hefei New Salt Pharmaceutical Engineering Research Center).
Our R&D center has more than 40 staff, 2 of them have Ph.D, 9 of them have master degree, 2 of them have pharmacist certificate.72 drugs in several core therapeutic areas have been registered in Chinese FDA, including liver diseases, hypolipidemic, respiratory diseases, antibiotics and diabetes. At present, we mainly focus on the development of Generic drugs. There are over 20 drug products, for both US and China market, in our ANDA product development pipeline. At the same time, the company's R & D center has applied for 7 national invention patents, of which 4 have been approved, and the rest have entered the stage of verification, among which two have been applied for international invention patents.
Pioneer established another research center in Shanghai with an investment about 10million Yuan in 2015. The center will take full advantage of the sufficient resource and information in Shanghai and focus on the drug research in health area. At present, the center has carried out strategic cooperation with famous domestic and foreign API manufacturers, and 2 projects have been successfully carried out.